San Diego-based Otonomy, a biopharmaceutical startup developing new treatments for diseases and disorders of the ear, has announced the estimated pricing of its initial public offering at $80 million — 5.3 million shares at a price range of $14 to $16.

Otonomy has applied to list on the NASDAQ Global Market as OTIC.

Earlier this year Otonomy secured $49 million in a Series D round of financing that brought the total capital raised to $144 million since 2008. Investors include Jennison Associates, OrbiMed Advisors, Novo Ventures, TPG Biotech, Avalon Ventures, Domain Associates, RiverVest Venture Partners, Aperture Venture Partners and Osage University Partners.